Danaher Corporation (DHR) shares soared 5.29% in pre-market trading on Wednesday, following the company's announcement of raised annual profit forecasts and better-than-expected quarterly results. The life sciences firm is leveraging steady demand for bioprocessing from its pharmaceutical clients and a recovery in the Chinese market to drive growth.

The company's strong performance has caught the attention of Wall Street analysts. Jefferies reiterated a Buy rating on Danaher with a price target of $230, while Scotiabank maintained its Buy rating with a $275 price target. TD Cowen raised its target price to $250 from $248, reflecting growing confidence in the company's prospects. Baird also maintained an Outperform rating on the stock.

Analysts are particularly optimistic about Danaher's bioprocessing strength, which is expected to help the company withstand macro headwinds. J.P. Morgan, which rates Danaher as "overweight" with a $260 price target, considers it a top pick due to its strong product portfolio that is relatively shielded from macro pressures. The company's strategic focus on bioprocessing and its recovery in China are seen as key drivers for future growth, with some analysts projecting 5-6% core growth for the business in 2026 if bioprocessing demand continues to pick up.